Beklazon-eco

Beklazon-eco is an inhalant used for various forms of bronchial asthma. We will become acquainted with his instruction and application features.

Inhalation glucocorticosteroid has a pronounced anti-inflammatory effect. It contains an active component - beclomethasone, which under the influence of esterases is transformed into an active derivative. The drug affects only the pulmonary system, and its long-term use reduces the risk of bronchospasm.

• The anti-inflammatory effect of aerosol is due to the inhibition of the development of an allergic reaction, that is, the metabolism of arachidonic acid.
• The active component improves mucociliary clearance and reduces the level of mast cells on the mucosa of the respiratory tract. This helps reduce the amount of inflammatory exudate and the severity of the epithelial edema, reduces the production of lymphokines and the hyperreactivity of the bronchi.
• Beclomethasone significantly slows the migration of macrophages, the severity of granulation and infiltration, which helps restore sensitivity to bronchodilators.

A noticeable therapeutic effect occurs on the 2-5th day, and the maximum therapeutic effect is 14 days after the initiation of therapy. Proceeding from this, the drug is not suitable for arresting acute attacks of asthma and bronchospasm. 

Indications Beklazon-eco

The main indication for the use of Beclason-eco is the treatment of various forms of bronchial asthma in children older than 4 years and in adults. Before prescribing the drug, the doctor instructs on the correct use of the inhaler to fully enter the drug in the right areas of the lungs.

With special care, medication is prescribed for patients with reduced function of the adrenal cortex. When using an inhaler, you must have a stock of glucocorticosteroids. This is connected with the risk of deterioration of the general condition, which can endanger life.

Release form

Beklazon-eco has a release form - aerosol for inhalation. One inhaler is designed for 200 doses of active substance. The activated breath contains 50, 100 and 250 μg of beclomethasone. Auxiliary components are: ethanol and hydrofluoroalkane (HFA-134a).

Aerosol is produced in aluminum cans under pressure. Each bottle has an outlet valve with a sprayer. The aerosol content is a colorless, odorless solution.

Beklazon-eco light breathing

An effective anti-asthmatic agent, inhalation with glucocorticosteroids - this is Beklazon-eco light breathing. The medicine helps with obstructive airway defeats.

Aerosol reduces inflammation and reduces swelling. A persistent curative effect develops on a 5-7 day course use. It is prescribed for patients of adult age and children older than 4 years. With special care is used for patients with chronic diseases of the kidneys and liver.

Pharmacodynamics

The active substance of the inhaler - beclomethasone dipropionate, has a weak tropicity to glucocorticosteroid receptors. Pharmacodynamics indicates its transformation into the active metabolite beclomethasone-17-monopropionate (B-17-MP) under the action of esterases (enzymatic substances contained in cells and catalyzing hydrolytic cleavage of esters). Metabolite has a pronounced local anti-inflammatory activity. Inflammation is reduced by the formation of a chemotactic substance, inhibition of an allergic reaction and improvement of mucociliary transport.

Beclomethasone reduces the volume of mast cells in the mucous membrane of the bronchi, reduces the epithelial edema and the secretion of bronchial mucus. Increased activity of beta-adrenoreceptors restores the body's response to bronchodilators, minimizing the frequency of their use. The drug does not have resorptive activity after inhalation. Does not stop acute attacks of bronchospasm.

Pharmacokinetics

After a single injection, about 56% of the dose taken is deposited in the lower respiratory tract. The remaining amount settles in the mouth, pharynx or is swallowed. Pharmacokinetics indicates the metabolism of the active substance to the metabolite B-17-MP. Systemic absorption occurs in the lungs of 36% and in the gastrointestinal tract 26%. Absolute bioavailability of the active substance is 2%, and its metabolite is 62% of the inhalation dose.

Beclomethasone dipropionate is rapidly absorbed, and its maximum concentration in the blood plasma is reached within 30 minutes. Between the system exposure and the increase in the inhaled dose there is a linear dependence. The distribution level in the tissues is 20 liters for the active ingredient and 424 liters for its metabolite. Binding to plasma proteins is high, as is plasma clearance. Half-life from 30 minutes to 3 hours.

Dosing and administration

Beclozan-eco and Beclozan-eco light breath contain the same doses of active substances, so these drugs are interchangeable. But each of them has its own peculiarities in the way of application and doses. Beklazon-eco is used only by inhalation.

• Adult patients are prescribed 100-500 mcg per day with a further maintenance dose of 200-400 mcg per day. In severe forms of asthma, up to 2000 micrograms per day can be used, but only under medical supervision.
• For children it is recommended to use 100-200 micrograms of beclomethasone per day. The maximum allowable dose is 200 mcg.

The daily dose should be divided into several injections. After achieving adequate control of asthma, the dosage of the drug should be adjusted to a minimum. A persistent therapeutic effect is observed on the 2-3 day of treatment. If the patient used other monoclonal drugs with beclomethasone before taking the inhaler, the dosage should be maintained.

Patients who are dependent on steroids need to monitor the functional activity of the adrenal cortex. In this case, before the use of aerosol, the patient's condition should be stable. The withdrawal of systemic drugs takes place one week after the start of treatment.

When treating children, it is necessary to regularly record growth rates, since the drug can cause its delay. In case of violations of the hypothalamic-pituitary-adrenal function, infections, surgical interventions and injuries, additional use of oral steroids may be required. The drug should be withdrawn gradually. It is very important to protect the eyes during the spraying of the aerosol.

Use Beklazon-eco during pregnancy

The possibility of using Beklazon-eco during pregnancy is determined by the attending physician. The drug is prescribed in the case when the potential benefit for the mother is higher than the risks for the fetus. As a rule, future mothers are prescribed safer drugs that do not have side effects or contraindications.

Contraindications

Aerosol for inhalation application Beklazon-eco is contraindicated for use in cases of intolerance to its components. The medicine is prohibited for acute asthma attacks and for children under four years of age.

With special care, the inhaler is prescribed for infections (fungal, bacterial, viral, parasitic), pulmonary tuberculosis, liver cirrhosis and kidney disease, osteoporosis, glaucoma and hypothyroidism.

Side effects Beklazon-eco

Incorrect use of the inhaler causes side effects. Beklazone-eco can cause such reactions:

• Candidiasis of the oral cavity and throat (with prolonged use of a dosage above 400 micrograms per day).
• Dysphonia and irritation of the pharyngeal mucosa.
• Paradoxical bronchospasm (short-acting inhaled beta2-adrenostimulants are used for its relief).
• Skin allergic reactions: itching, rashes, urticaria, swelling of the face and mucous membrane of the throat.

Also, adverse symptoms caused by systemic action of the medication are possible: headaches, nausea, bruising and thinning of the skin, a decrease in the function of the adrenal cortex, unpleasant gustatory sensations, osteoporosis, glaucoma, cataracts, growth retardation in children.

[1]

Overdose

Symptoms of an overdose of the drug can provoke a temporary decline in the function of the adrenal cortex. To eliminate this condition, emergency therapy is not required, since the functions of the adrenal cortex are restored within the next few days (confirmed by the level of cortisol in the blood plasma).

Interactions with other drugs

With the simultaneous use of an inhaler with barbiturates with phenytoin or rifampicin, metabolism may increase and the effect of oral glucocorticosteroids may decrease. Interaction with other drugs is controlled by the attending physician. If adverse reactions to anticoagulants are observed, correction of their dose is required. When using Beklazon-eco with oral corticosteroids or diuretics, there may be increased loss of potassium.

[2], [3]

Storage conditions

According to the storage conditions, the inhaler should be kept at a temperature of no higher than 30 ° C in a place protected from sunlight and inaccessible to children. Since the cartridge contains liquid under pressure, it is forbidden to pierce, break or heat, even after the full use of the medicine. Also it is forbidden to freeze or cool.

Shelf life

Beklazon-eco has a shelf life of 36 months (indicated on the can). After the end of treatment, the aerosol must be disposed of. An overdue inhaler is prohibited for use, as it can provoke uncontrolled adverse reactions.